Diabetic Medicine
Manufacturer in India

WHO-GMP certified antidiabetic medicine manufacturing — Biguanides, Sulfonylureas, DPP-4 inhibitors and SGLT-2 agents across tablets and capsules — for domestic institutional supply, government procurement programmes and international export.

Key Highlights

WHO-GMP
Certified Facility
Metformin · Glimepiride
· DPP-4 · SGLT-2
15+ Countries
Supplied
DCGI Approved
Formulations

Request A Product List

Download Capability Brochure

About Diabetic Care

Antidiabetic medicine manufacturing
expertise at 9M India

9M India manufactures a comprehensive range of antidiabetic medicines from a WHO-GMP certified facility in Birkoni, Chhattisgarh. Our antidiabetic portfolio spans four major drug classes — Biguanides (Metformin), Sulfonylureas (Glimepiride, Glibenclamide), DPP-4 inhibitors (Sitagliptin, Vildagliptin) and newer SGLT-2 inhibitors (Dapagliflozin) — available as tablets and capsules in immediate-release and extended-release formats.

Diabetes is the fastest-growing non-communicable disease globally with over 77 million patients in India alone. Antidiabetic medicines — particularly Metformin as first-line therapy — represent one of the highest-volume and most consistently tendered medicine categories in government health programmes, state formularies and international export contracts. Metformin tablets (500mg, 850mg and 1000mg) including extended-release formulations are manufactured at commercial scale with validated dissolution profiles confirming sustained-release performance.

Every antidiabetic formulation at 9M India carries valid DCGI manufacturing approvals and is
supported by complete regulatory documentation for institutional tender and export registration
submission.

Antidiabetic medicines across Biguanides, Sulfonylureas, DPP-4 inhibitors, SGLT-2 agents
Metformin tablets in IR and ER (extended-release) formats — multiple strengths
Fixed-dose combination antidiabetic tablets — Metformin + Glimepiride, Metformin + Sitagliptin
WHO-GMP certified with in-house dissolution and assay testing
DCGI-approved — export-ready with complete regulatory documentation

Enquire Now

Our Capabilities

Antidiabetic medicine manufacturing
capabilities at 9M India

01

Metformin hydrochloride tablets are manufactured in immediate-release (500mg, 850mg, 1000mg) and extended-release (Metformin XR — 500mg, 750mg, 1000mg) formats. Extended- release Metformin tablets use hydrophilic matrix technology — hydroxypropyl methylcellulose (HPMC) polymer matrices — with validated dissolution profiles demonstrating controlled drug release over 8–12 hours. Dissolution testing using USP Apparatus 2 at multiple pH values confirms extended-release performance and batch-to-batch consistency.
02

Glimepiride tablets in 1mg, 2mg and 4mg strengths — low-dose tablet manufacturing requiring enhanced blend uniformity validation and rigorous content uniformity testing by HPLC. Glibenclamide tablets (2.5mg and 5mg) for type 2 diabetes management. All sulfonylurea tablets manufactured with validated low-dose tablet blend uniformity protocols — critical given the narrow therapeutic index and dose-dependent hypoglycaemia risk of this drug class.
03

Sitagliptin tablets (25mg, 50mg, 100mg) and Vildagliptin tablets — DPP-4 inhibitor antidiabetics with increasing prescription and export demand. Dapagliflozin capsules (10mg) — SGLT-2 inhibitor representing the newest class of oral antidiabetic agents with rapidly growing global prescription volumes. Fixed-dose combination tablets — Metformin + Glimepiride, Metformin + Sitagliptin, Metformin + Dapagliflozin — manufactured with validated individual and combined content uniformity for both active components.
04

Fixed-dose combination antidiabetic tablets represent a growing segment — combining first-line therapy (Metformin) with second-line agents (Glimepiride, Sitagliptin, Dapagliflozin) in a single tablet to improve patient compliance. Manufacturing of combination tablets requires validated content uniformity for each active component independently, compatible dissolution profiles across both APIs simultaneously and confirmed compatibility between APIs and shared excipients across shelf life.
05

Antidiabetic medicines are core items in every state essential medicines list, NHM formulary and CGHS/ESIC approved medicine list. Our DCGI-approved antidiabetic formulations are supported by complete documentation — Manufacturing Licence, WHO-GMP Certificate, COA, COC, stability data and dissolution profiles — pre-prepared for institutional tender bid submission. For export markets, complete dossier support for regulatory registration in Africa and South-East Asia is available.

Antidiabetic formulations across dosage forms

Tablets
- Standard IR
- Extended-release
- Film-coated
- Fixed-dose combinations
- Biguanides
- Sulfonylureas
- DPP-4 inhibitors
- SGLT-2
- Metformin
- Glimepiride
- Sitagliptin
- Dapagliflozin
Capsules
- Hard gelatin
- Immediate-release
- Biguanides
- SGLT-2 inhibitors
- Newer agents
- Metformin capsules
- Dapagliflozin capsules

Why Choose Us

Why choose 9M India for antidiabetic
medicine manufacturing

9M India stands out for its commitment to quality, precision, and innovation in tablet manufacturing. Our production facilities, regulatory compliance, and skilled teams ensure consistently reliable outcomes. We focus on delivering safe, effective, and high-performance formulations tailored to therapeutic needs, making us a trusted partner for brands seeking dependable pharmaceutical manufacturing excellence.

Metformin IR and XR. Validated extended-release performance.

Metformin immediate-release and extended-release tablets — both manufactured at 9M India. XR formulations validated with multi-point dissolution profiles confirming controlled release. This is not a claim — it is what dissolution data demonstrates.
Low-dose sulfonylurea manufacturing. Enhanced validation as standard.

Glimepiride at 1mg and 2mg requires enhanced blend uniformity validation — not achievable without validated low-dose tablet manufacturing processes. 9M India applies the enhanced protocols that low-dose antidiabetic manufacturing requires.
Combination antidiabetic tablets. Both actives. Fully validated.

Metformin + Glimepiride and Metformin + Sitagliptin combination tablets — validated content uniformity for both APIs, compatible dissolution and confirmed shelf-life stability. Documentation supports both domestic formulary and export registration requirements.

Our Diabetic Care Range

Key antidiabetic formulations
manufactured at 9M India

9M India offers diverse tablet variants designed for reliable performance, quality assurance, and fulfilling therapeutic requirements.

01

Metformin 500mg | Antidiabetic | Standard IR tablet | Biguanide
02

Metformin 1000mg | Antidiabetic | Extended-release tablet | Biguanide
03

Glimepiride 1mg | Antidiabetic | Standard tablet | Sulfonylurea
04

Glimepiride 2mg | Antidiabetic | Standard tablet | Sulfonylurea
05

Glimepiride 4mg | Antidiabetic | Standard tablet | Sulfonylurea
06

Glibenclamide 5mg | Antidiabetic | Standard tablet | Sulfonylurea
07

Sitagliptin 100mg | Antidiabetic | Film-coated tablet | DPP-4 inhibitor
08

Vildagliptin 50mg | Antidiabetic | Film-coated tablet | DPP-4 inhibitor
09

Dapagliflozin 10mg | Antidiabetic | Film-coated tablet | SGLT-2 inhibitor
10

Metformin + Glimepiride | Antidiabetic | Combination tablet | Biguanide + Sulfonylurea
11

Metformin + Sitagliptin | Antidiabetic | Combination tablet | Biguanide + DPP-4
12

Metformin + Dapagliflozin | Antidiabetic | Combination tablet | Biguanide + SGLT-2

We keep answer short

Frequently asked questions —
antidiabetic medicine manufacturing

Frequently asked questions in tablet manufacturing address processes, quality standards, formulation methods, regulatory compliance, and production capabilities, helping clients.

01

Biguanides (Metformin), Sulfonylureas (Glimepiride, Glibenclamide), DPP-4 inhibitors (Sitagliptin, Vildagliptin) and SGLT-2 inhibitors (Dapagliflozin) — plus fixed-dose combination antidiabetic tablets.
02

Yes — Metformin XR in 500mg, 750mg and 1000mg strengths using HPMC matrix technology. Validated dissolution profiles confirming extended-release performance available on request.
03

Yes — Metformin + Glimepiride, Metformin + Sitagliptin and Metformin + Dapagliflozin. All combinations validated for individual API content uniformity and combined dissolution profiles.
04

Yes — Metformin and Glimepiride are core items on state essential medicines lists and NHM formularies. DCGI-approved with documentation pre-prepared for bid submission.
05

Yes — Dapagliflozin 10mg film-coated tablets manufactured under WHO-GMP standards. This newer antidiabetic class has rapidly growing prescription and export demand.